

Registered number: 06541016
Charity number: 1126927

**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT
DIABETES**

(A Company Limited by Guarantee)

**TRUSTEES' REPORT, INDEPENDENT EXAMINER'S REPORT AND FINANCIAL
STATEMENTS**

FOR THE PERIOD ENDED 31 DECEMBER 2023

SATURDAY



ADCLHØFU

A16

28/09/2024

#480

COMPANIES HOUSE

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, Its Trustees and Advisers	1
Trustees' Report	2 - 11
Independent Examiner's Report	12 - 13
Statement of Financial Activities	14
Balance Sheet	15
Statement of Cash Flows	16
Notes to the Financial Statements	17 - 33

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2023

Trustees	Professor David Maahs, President Dr Lars Krogvold, Treasurer (resigned 20 October 2023) Dr Carine de Beaufort, Past President (resigned 14 October 2022) Dr Jamie Wood, Secretary General Dr Sabine Hofer, Treasurer (appointed 20 October 2023)
Company registered number	06641016
Charity registered number	1126927
Registered office	Ellenborough House Wellington Street Cheltenham Gloucestershire GL50 1YD
Management Company / Principal Office	K.I.T. Group GmbH
Company secretary	Dr Jamie Wood
Independent Examiner	Crowe U.K. LLP Chartered Accountants Black Country House Rounds Green Road Oldbury West Midlands B69 2DG
Bankers	Commerzbank Berlin-Gedächtniskirche Kurfürstendamm 237 10719 Berlin Germany Lloyds Bank Plc Rotunda Montpellier Cheltenham Gloucestershire GL50 1SH

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees under Charity Law, who are also the Directors under Company Law, present their report and the financial statements of the Charity for the period ended 31 December 2023. This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The International Society for Paediatric and Adolescent Diabetes – ISPAD - is a charitable company, limited by guarantee, incorporated on 8 July 2008 (registration number 06641016) and registered as a charity on 25 November 2008 (charity number 1126927).

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

The International Society for Paediatric and Adolescent Diabetes (ISPAD or the Society) is governed by its Memorandum and Articles of Association dated 8 July 2008 (last amended 13 June 2023); and the UK Charity Governance Code.

Principal Activity

ISPADs overall mission is to bring together professionals from various disciplines with an interest in clinical care, science, education, and advocacy to prevent, treat or cure all forms of diabetes in youth by promoting networking and collaboration. The principal activity of ISPAD is to improve the lives of children, adolescents and young adults with diabetes worldwide, which is accomplished by providing forums, both written (guidelines) and face-to-face (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. To advance further these aims, ISPAD advocates throughout the world for the appropriate provision of medical care and assists international organisations and health services in the delivery of critical diabetes self-care supplies, such as insulin and glucose test strips, together with educational and promotional material for all children and adolescents with diabetes.

Organisational Management

Each officer of the Charity has a role and responsibilities that are enumerated in the governing document. The Society's focus on Science, Advocacy and Education is ensured by the officers of the Society who serve as Trustees. They have the ultimate responsibility for fiscal and other decisions in accordance with the Memorandum and Articles of Association, and any bylaws. They consult with the advisory council composed of members of the Society elected each year at the Annual Conference. Advisory council members are specifically sought from different regions of the world so that they are representative of the membership as a whole. The advisory council formally meets with the board twice each year. Between meetings information is exchanged by e-mail and regular conference calls. The dissemination of information on important issues does not need to wait for formal meetings.

The Trustees retain an organisational management group (K.I.T. Group GmbH, Berlin, Germany) who deal with the day-to-day activities of the Society and advises the Trustees in this regard. They have the ability to allocate their employees in any manner that best serves the Society and are granted a license to organise and manage the Annual Conference, the venue for which is selected by the Executive Board. K.I.T. Group reviews the locations, budgets and logistics for the Society and signs the contracts between the management group and venues and exhibitors. K.I.T. Group also collaborates with and provides logistical support to the local conveners and international Scientific Committee, which creates the scientific program and selects speakers.

The management group maintains for the Society records of day-to-day financial transactions and provides reports to the Treasurer and other Trustees at regular intervals. K.I.T. Group processes receipts and transfers funds from the Society's accounts (used for day-to-day activities) with the approval of the Treasurer, or the Trustees as a whole, during Trustee meetings or after discussions with Trustees. They organise the venue and related activities for Directors' meetings. The Charity retains both an accounting firm and solicitors. These advise the Trustees on governance, legal, and financial issues.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Recruitment and Training of Trustees

The Trustees of the Society are the current serving officers of the Society. The Trustees are elected by the members at the Annual Conference. The processes for nomination and election of the Trustees are outlined in the Articles and Memorandum (amended 12 October 2012 to allow electronic voting). Trustees have been members of the Society for many years and have contributed to the Society in many areas; e.g., serving on the Advisory Council, organising one or more of the Annual Scientific meetings, science schools or postgraduate courses. Trustees have contributed to the Society's efforts in Science, Education and Advocacy, which are the pillars of the Society.

Newly elected Trustees spend one year as Trustee-elect and attend the Board/Trustee meetings to gain experience in the Society's activities: charity governance, finances, grant processing/approvals and other issues involving the organisation and running of the Society. Trustees must be members in good standing of the Society and have participated in the Society's activities in leadership roles. They receive formal information about the role and responsibilities of a Trustee, and undertake self-paced learning from documents available through the Charity Commission. The year spent serving as Trustee-elect allows on the job experience, guidance and education from the current Trustees prior to assuming the responsibility of a Trustee.

Structure and Relationships

The Trustees/Board of Directors communicate with each other (usually via email) almost daily on the management and direction of the Charity. A regular formal video conference meeting is arranged monthly between the Officers and the Administration Company.

The Trustees retain an organisational management group to assist with the actual day-to-day management of the Charity and the Board has direct oversight of their activities. The Society contracts with the management group to organise and manage the Annual Conference. The management group also provide material support for meetings, organises the Annual Report with the Trustees, which is prepared for distribution at the Annual General Meeting (and available for consultation in the member area on the ISPAD website) and provides a post-conference report for the Trustees after the Annual Conference.

Formal management reports are presented to the Trustees at face-to-face meetings at least twice per year. A written report is presented to the Trustees and members at the Annual General Meeting. Information is exchanged by e-mail or telephone frequently on an 'as needed' basis. Financial reports are given to the Treasurer regularly, and the Trustees are updated regularly.

The Trustees, on behalf of the Society, established in 2000 a contract with Wiley, the then publisher of the Society's journal, *Pediatric Diabetes*, to provide subscriptions to the journal to all ISPAD members. ISPAD decided to end its relationship with *Pediatric Diabetes* at the end of 2022 in response to Wiley transferring the journal to Hindawi with dramatic editorial, publishing, and financial changes, including a refusal to publish future ISPAD Guidelines. The Trustees worked on new journal partnership opportunities for ISPAD, including publication of ISPAD Guidelines, and established a contract with Karger in June 2024. Subscription to the *Journal Hormone Research in Paediatrics* published by Karger is provided for all ISPAD members. Members will have full online access, will be nominated to the Editorial Board of the journal, the ISPAD Guidelines and other society reports will be published in the journal.

The Society has established agreements of cooperation, collaboration and Memoranda of Understanding with other Charities, companies and Medical Professional Organisations with similar objectives and aims on a need's basis.

The Trustees contract for facility space, audio-visual supplies and support, and food for the Winter administration meeting (usually held during the international conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Europe) and the Summer meeting usually held during the American Diabetes Association Annual Scientific Meeting (ADA) in the United States.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees set policies and guidelines for organising and running the Annual Conference. The Trustees, on behalf of the Society, provide scientific oversight and work closely with the conveners and international scientific committee on the program of the Annual Conference.

Risk Management

By contractual agreement, the management group shares the financial risk for the Annual Conference, which usually attracts at least 1,000 attendees from around the world. ISPAD maintains a substantial amount of reserve funds and does not spend money unless convinced that so doing is consistent with the mission of ISPAD, likely to be beneficial and will not deplete its reserves.

The Trustees conduct an annual review of all types of risk by which the Society may be affected. Having reviewed these risks, the Trustees are satisfied that appropriate systems are in place to manage exposure to major risks. The Society holds Trustee liability insurance.

Governance

The Trustees of ISPAD are committed to the Society's mission and have joined its board because they want to help the charity most effectively carry out its mission for the benefit of children, adolescents, young people and families with diabetes. Trustees fully recognise that meeting their charity's stated public benefit is an ongoing requirement, understand their roles and legal responsibilities, and are committed to good governance, and wish to contribute to ISPAD's continued improvement.

The board acts with integrity, adopting values and creating a culture that helps achieve the organisation's charitable purposes. The board is aware of the importance of the public's confidence and trust in charities, and trustees undertake their duties accordingly.

Trustees have the ultimate fiduciary responsibility for managing ISPAD's funds and assets, protecting its reputation, and maintaining the respect of beneficiaries, other stakeholders and the public by behaving with integrity at all times, even when difficult or unpopular decisions are required.

The board leads the organisation in being transparent and accountable. The charity is open in its work, unless there is good reason for it not to be. The public's trust that a charity is delivering a public benefit is fundamental to its reputation and success. Making accountability real, through genuine and open two-way communication that celebrates successes and demonstrates willingness to learn from mistakes, helps to build this trust and confidence and earn legitimacy.

OUR VISION, MISSION, AND VALUES

Our Vision

A better world for children, adolescents and young adults with diabetes.

Mission Statement

To bring together professionals from various disciplines with an interest in clinical care, science, education and advocacy to prevent, treat or cure all forms of diabetes in youth.

By promoting networking and collaboration, our aims are:

- To ensure appropriate treatment is available, including medication, self-monitoring equipment and supplies;
- To increase awareness of all types of diabetes and prevent delayed diagnosis;
- To reduce the morbidity and mortality caused by acute and chronic complications;
- To ensure provision of education to youth, families and other caregivers;
- To promote education of diabetes healthcare teams worldwide;
- To foster diabetes research; and
- To prepare and disseminate clinical practice guidelines and standards.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Our Values

Excellence

In care, based on rigorous and ethical research with respect for the individual child, adolescent and family and by creating, evaluating and disseminating diabetes knowledge.

Collaboration

The Society collaborates with national and international patient and professional organisations, healthcare providers, policy makers and companies that make products or provide services for children with diabetes.

Advocacy

For children and caregivers to improve awareness that diabetes is different for children compared to adults; to end discrimination based on a child's diabetes; and to obtain increased funding for diabetes treatment, research and prevention.

- To promote the care of children and adolescents with all forms of diabetes mellitus;
- To be an advocate for children and adolescents with all forms of diabetes mellitus; and
- To encourage and support basic, clinical, epidemiological, health, economic and all other relevant research concerning paediatric and adolescent diabetes mellitus.

Public Benefit

Please see below a summary of the principal activities and accomplishments for the year which ISPAD has carried out for the public benefit.

In the furtherance of these objectives, the ISPAD Trustees have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's published general and relevant sub-sector guidance concerning the operation of the Public Benefit requirement under that Act.

PRINCIPAL ACTIVITIES AND ACCOMPLISHMENTS

Education

The extensive Clinical Practice Consensus Guidelines (26 chapters), published in 2022, continue to be promulgated and made available on the Society's website and published in Paediatric Diabetes, the Society's former journal. The Clinical Practice Consensus Guidelines are an up-to-date reference for all those concerned with the management of childhood diabetes worldwide and include guidelines for under resourced areas. The Guidelines were developed and written by members of the Society, led by an editorial team. This last comprehensive revision consists of 26 chapters and over 250 authors (global distribution, early career and senior, diverse professional background, and persons with diabetes). In addition, an external project officer was appointed to take a lead in supporting the editorial team to ensure the guidelines meet international standards for clinical guidelines and ensure harmonisation of recommendations, content, language and evidence grading across chapters.

The Guidelines are evidence-based and are written using a review process involving input from the entire membership, led by our excellent and enthusiastic volunteer editorial team. A copy of each chapter is available for download by anyone (not only for the members) at no cost from our website www.ispad.org. ISPAD is currently collaborating with partners on the translation of the ISPAD 2022 Guidelines into various languages to facilitate access. By today, the Guidelines are available English, French, Spanish, Portuguese and Hindi. In addition, translations into other languages are encouraged with no charge from ISPAD who coordinates these efforts to avoid redundant translations.

Educational courses are offered to the membership both, in virtual format (Webinars, online learning tools) and in person Annual Conference, Science Schools for Physicians and Healthcare Professionals, as well as Postgraduate Courses).

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Advocacy

ISPAD collaborates closely with 'Life for a Child' and 'Changing Diabetes in Children' two major programs whose aim is to improve access to essential diabetes medicines (insulin) and supplies for children in the developing world. ISPAD also collaborates with 'Action4Diabetes', a charity providing health to disadvantaged young people with Diabetes in South-East Asia.

ISPAD continues to work with European Union partners (e.g. EU Diabetes Forum) to improve the quality of care throughout the world.

ISPAD opened its membership for advocates and offers a separate membership for advocates.

Science

The Annual Conferences involve presentation of research activities, state-of-the-art lectures and topic specific symposia. In 2020 and 2021, ISPAD's Annual Conference took place virtually over a three-day meeting in October 2020 and 2021 with 1,285 and 1,414 participants respectively. In 2022, the Annual Conference was held in person in Abu Dhabi, United Arab Emirates October 13-16. In total, the meeting brought together 1058 Attendees (781 Face to Face, 277 Virtual), and 369 scientific abstracts were submitted. In 2023, the Annual Conference was held in Rotterdam, Netherlands with a total of 1,623 Attendees from 100 countries and 489 abstracts submitted by authors from all parts of the world.

ISPAD organises and runs, with volunteer experts, an annual research-oriented Science School for Physicians (held in person in Verbania, Italy, in April 2023), as well as a Science School for Allied Healthcare Professionals working in diabetes (held in person in Rotterdam in October 2023). Applications are competitive for both science schools each year.

Visiting Fellowships allow young physicians and healthcare professionals to study research techniques and prepare them to set up research, either in collaboration with the centre in which they study, or to initiate research in a similar area in a more independent manner by providing hands-on experience in an established Centre of Excellence of research in the domain of interest. Applicants present a research proposal for their study as well as references, with letters of support from their hospital or university and from the head of the research centre to which they are applying (directed by an ISPAD member) attesting to the applicant's acceptance at the centre to pursue the research project as presented. The accepting ISPAD member volunteers their time and centre resources for the project. The funds allow the recipient to travel to the centre and provide support for accommodation. Since 2017 ISPAD collaborates with Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation (JDRF)) and awards 4 research fellowship, 25,000 dollars each, and since the calendar year 2019, 10 Allan Drash fellowships, of 7,500 dollars each. From 2024 onwards, the funding of the Research Fellowship will increase to 25,000-40,000 dollars range to fund up to 6 fellows.

The applications are reviewed by the Trustees and the Advisory Committee who rank them on the quality of the application and potential benefits to the applicant. The successful recipient provides ISPAD with a report on the project and is encouraged to submit an abstract to the Annual Conference and/or submit a manuscript to the ISPAD journal.

Grants from General Funds

Travel grants are for young physicians and healthcare professionals whose abstracts have been accepted for presentation at the Annual Conference. ISPAD support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world).

The abstract quality (scoring as per reviewing process by the Abstract Committee) as well as the country of residence and profession were part of the selection criteria for allocating these grants. Applications from Lower Income Countries (as per World Bank classification) and Allied Healthcare Professionals were explicitly encouraged.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Grants Supported by Funds from Restricted Grants

Grants were obtained for the Science School for Physicians for a 5-day course for 23 young physician scientists (in 2023) to learn how to design a research study, apply proper statistics and write grants. These grants were provided in 2023 by Breakthrough T1D (formerly JDRF).

Volunteers

Members of the Society participate in all aspects of the Society e.g.:

- serving on the Advisory Council
- serving as convener and organising committee members for the Annual Conference
- serving on the Scientific Committee
- reviewing abstracts for the Annual Conference
- acting as faculty for the Science Schools and post graduate courses
- serving on writing committees for the Clinical Practice Guidelines
- serving on special interest group
- advocating for children with diabetes at local, regional and international levels
- working with sponsors to increase contributions
- attending the Annual Conference (primary fund-raising event)
- serving as preceptors for Visiting Fellows
- providing leadership in diabetes care for children and adolescents locally.

Members

The International Society for Paediatric and Adolescent Diabetes has members from more than 100 countries. A membership directory can be found on the ISPAD website (www.ispad.org).

FINANCIAL REVIEW AND RESULTS FOR THE PERIOD

Financial Review

The current period is for the 12 month-period ended 31 December 2023 ('2023'). The prior period is for the year ended 31 December 2022 ('2022').

During the financial period 1 January 2023 to 31 December 2023, expenditure totalled £751,172 (2022: £730,423) and income was £967,848 (2022: £848,597).

Our financial goals are to maintain sufficient funds held in reserve to assure our continued existence under difficult financial situations (poor income years, and unusual economic times), while we continue to support funding for Science Schools, Post Graduate Courses, the Allan Drash Clinical Fellowship, Research Fellowship, Travel Grants, Hormone Research in Paediatrics, Guideline officer, Memberships, and special initiatives.

One of the challenges of holding our Annual Conferences in different locations around the world is the widely varying costs and benefits from them. The 2018 Conference in Hyderabad, India was a successful Conference in raising awareness across the wider region, but resulted in a negative balance, while the 45th Annual Conference in Boston, USA in 2019 resulted in a positive balance. The Annual Conferences in 2020 and 2021 were both virtual, with good attendance and they resulted in positive balances.

The Annual Conference in 2023 took place in Rotterdam, Netherlands and was a very successful meeting with the highest number of attendees in our history and resulted in a positive balance.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

A crucial element of our charitable aims is to facilitate access to science and education, especially for young health professionals involved with diabetes. To this end we support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world). Starting from July 1, 2020, ISPAD has reduced membership and registration fees for members from Upper-middle-income countries as well as waived membership fees for Low-income countries.

Reserves Policy

Our policy is to maintain reserves of sufficient funds to provide ongoing support for at least one year of Charity activity. ISPAD currently aims to keep reserves of £700,000. The balance of total reserves at the year end was £1,487,719 (2022: £1,271,043) of which £1,170,128 (2022: £1,135,179) was free reserves, this compares with £967,848 of total income in the period ended 31 December 2023 (2022: £848,597), and £486,413 (2022: £135,864) was restricted. Conference income is very unpredictable and the current financial climate demands that we hold a slightly increased reserve. This is considered to be prudent also in light of the fact that corporate sponsorship has become more challenging to obtain.

Investment Policy and Objectives

The overriding philosophy and policy is that the Charity will take only minimal risk in order to preserve funds. The objectives are to garner when possible, reasonable interest on held funds without placing reserves or day-to-day funds at risk.

Income:

During 2022, we again observed an increase in total membership numbers, mainly because the in-person conference in Abu Dhabi raised local interest and new members from the area. Our Annual Conference in Rotterdam 2023 was very well attended and also affected our membership numbers. ISPAD will continue to work hard in order to increase the numbers of members, both in specific regions as well as worldwide.

Regarding Corporate Membership and Sponsorship, which are extremely important sources of income for ISPAD, the situation is still uncertain. So far, all key sponsors have maintained their commitments. Still, we are aware that the situation for many of our Corporate collaborators are uncertain, and we should not take their support for granted for the upcoming years.

The Annual Conference in Rotterdam 2023, resulted in a positive balance. This was both because of an increase in number of attendees and increase in sponsorship income, positively influenced by the realisation of our meeting in Europe.

Expenses:

There are still, and will most likely always be, uncertainties with respects to the allocation and format of several of ISPAD core activities. This includes our science schools, both for physicians and healthcare providers, the ASPED-ISPAD-Lilly Academy, CDiC training, ADECA training and finally the Allan Drash fellowships. The restricted funding from different sponsors for these activities will depend on the activities' format (in-person or virtual). These activities are of course very important for ISPAD as society, and we have to be flexible, dynamic and pragmatic to maintain as many as them as well, even though the situation caused by the pandemic may return.

In summary, there are more risks and uncertainties than usual in the current situation. Nonetheless, the financial situation is very safe within the fiscal year 2023 due to headroom given by the high level of reserves.

The Trustees undertake detailed planning and forecasting across the year. Due to this, the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Looking ahead

ISPAD has increased engagement with patient advocacy groups during this reporting year, and has encouraged them to meet at our Annual Conferences and to publicise the work and mission of ISPAD. ISPAD has played a major role in communication with the community about COVID-19 safe practices and effects on the diabetes community during 2021, and continued so in 2022. Our Annual Conference for 2024 will be on site in Lisbon, Portugal. At the annual meeting the Society will also celebrate its 50th anniversary.

Due to the COVID-19 pandemic, the international conflicts and climate changes, the financial situation is still challenging and rules and regulations for support from industry have changed making it more difficult for ISPAD to receive corporate membership fees or specific grants. We are grateful for those who have been able to continue to support ISPAD. For this reason, ISPAD offers different levels to become a corporate member or sponsor, with different benefits. ISPAD, to enhance its relationship with companies, organizes a specific and strategic meeting (Corporate Advisory Board Meeting) annually with all companies during its Winter Meeting. Since 2019, this meeting has been taking place adjacent to the ATTD (Advanced Technologies and Treatments in Diabetes) in order to enable maximum industry attendance. Furthermore the Executive Board Members meet with industry partners at the Summer Meeting (taking place at ADA – American Diabetes Association) and of course during the ISPAD Annual Conference in autumn every year. The invoiced year for corporate membership is now the Calendar year (January to December).

Membership payments are becoming increasingly important. The number of lapsed members might be significantly reduced by improving the payment process and the possibilities to interact with other members. In order to improve payment of membership fees and to overcome some technical issues, ISPAD has requested K.I.T Group GmbH to improve the membership system and extend on the overall experience to enrol members in ISPAD activities. Now, after 9 years from its implementation the system appears to be working well and membership had been steadily increasing every year until COVID-19. As we hoped, we could stabilize our Membership and slightly increase our membership income in 2023. We are aiming to further increase our membership due to the upcoming Annual Conference in Lisbon, Portugal. To enhance the member experience and modernize its online presence, ISPAD will be launching a new membership software and an upgraded website in 2024.

We still anticipate that ISPAD will likely face the late consequences of the COVID-19 pandemic and global inflation in the upcoming fiscal years. We expect that some corporate members and sponsors may withdraw as their financial situation is uncertain. Although others may become new members, we may see a reduction in total corporate members and sponsorships. Although we are organising the Annual Conference on-site in presence and hybrid mode, we are unsure how the rise in flight prices will affect travelling and thus congress activity and participation. Therefore, maintaining reserves of sufficient funds are more important than ever for ISPAD.

We have also initiated a revised accounting system for invoicing to be performed by K.I.T. Group in conjunction with and approval by the ISPAD Treasurer. This system is designed to provide redundancy and avoid missing opportunities for ISPAD funding.

Charity Governance Code

ISPAD aims to address the seven principles of the Charity Governance Code
<https://www.charitygovernancecode.org/en/front-page>

1. Organisational purpose: to facilitate the mission of ISPAD to improve the lives of children, adolescents and young adults with diabetes worldwide. To do this we provide forums, both written (guidelines, e-Learning) and face-to-face (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. We have three main pillars to achieve our mission: science, education and advocacy.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Leadership; the Trustees comprise an Executive Board and are advised by an Advisory Committee. We take collective responsibility for the Board's decisions. The roles of each Trustee are clearly identified (Winter Executive Meeting February 2020). Since 2017, the Executive Board now includes a Communications Director to facilitate effective communication with the membership and community.
3. Integrity; the Executive Board acts with integrity and is conscious of how it is perceived by the membership and the public. A corporate liaison officer was appointed in February 2018 to assist with communication and perception in the community, the "Diabetes Online Community" including consumer "bloggers". We facilitate their meetings at our Annual Conference and meet with them at meetings organized by the consumer organization Children With Diabetes (February 2020). Conflicts of interest are declared.
4. Decision-making, risk and control; the Board makes sure that operational plans and budgets are in line with the charity's purpose. The Board invested in forward planning by expenses for representatives to meet and teach in India (2016-2020), the country with the second largest number of children with diabetes, and in Africa (2019, 2020, 2022, 2023)
5. Board effectiveness; the Board acts as an effective team and encourages members of the Advisory Board to set up Special Interest Groups at the Annual Conference in October 2017 onwards. Trustees are reflective of their performance and discuss areas that can be strengthened.
6. Equality, Diversity and Inclusion; the Board encourages diversity in the membership of committees, and in special non-physician positions on the Advisory Board.
7. Openness and accountability; the Board communicates with the membership by the Annual General Meeting and by monthly newsletters sent by email. The President writes special messages since 2017 which can be sourced on the Society's website. The Annual Report is circulated to the Membership and is available to the Public.

Statement of Trustees' Responsibilities

The Trustees (who are also directors of the International Society for Paediatric and Adolescent Diabetes for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charitable Company and of the incoming resources and application of resources, including the income and expenditure, of the Charitable Company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charitable Company will continue in business.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charitable Company's transactions, disclose with reasonable accuracy at any time the financial position of the Charitable Company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the Charity's constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The report of the Trustees has been prepared in accordance with the special provisions relating to small companies subject to the small companies regime within part 15 of the Companies Act 2006.

Approved by the Board of Trustees of The International Society for Paediatric and Adolescent Diabetes on
27/09/2024 and signed on its behalf by:


Dr Sabine Hofer
Trustee

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Independent Examiner's Report to the Trustees of The International Society for Pediatric and Adolescent Diabetes ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the period ended 31 December 2023.

This report is made solely to the charitable company's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and the charitable company's trustees as a body in accordance with section 154 of the Charities Act 2011. My independent examiner's work has been undertaken so that I might state to the charitable company's trustees those matters I am required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body for my independent examiner's work, for this report, or the opinions I have formed.

Responsibilities and Basis of Report

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Signed:

Helen Blundell

Dated: 27 September 2024

Helen Blundell

LLB FCA FCIE DChA

Crowe U.K. LLP

Chartered Accountants

Black Country House

Rounds Green Road

Oldbury

West Midlands

B69 2DG

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:					
Donations		47	-	47	-
Charitable activities:					
Membership income		105,698	-	105,698	144,305
Corporate sponsorship income		-	486,413	486,413	316,918
Corporate membership		161,136	-	161,136	132,878
JDRF Fellowship		-	-	-	156,652
Conference income		201,696	-	201,696	84,589
Other income: Royalties		12,858	-	12,858	13,255
Total income		481,435	486,413	967,848	848,597
Expenditure on:					
Charitable activities	4	414,255	336,917	751,172	730,423
Total expenditure		414,255	336,917	751,172	730,423
Net income		67,180	149,496	216,676	118,174
Transfers between funds	14	(32,231)	32,231	-	-
Net movement in funds		34,949	181,727	216,676	118,174
Reconciliation of funds:					
Total funds brought forward		1,135,179	135,864	1,271,043	1,152,869
Net movement in funds		34,949	181,727	216,676	118,174
Total funds carried forward		1,170,128	317,591	1,487,719	1,271,043

The notes on pages 17 to 33 form part of these financial statements.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)
REGISTERED NUMBER: 06641016

BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	2023 £	2022 £
Current assets			
Debtors	11	141,699	285,838
Cash at bank and in hand		1,832,702	1,572,277
		<u>1,974,401</u>	<u>1,858,115</u>
Creditors: amounts falling due within one year	12	(450,341)	(543,825)
Net current assets		<u>1,524,060</u>	<u>1,314,290</u>
Total assets less current liabilities		<u>1,524,060</u>	<u>1,314,290</u>
Creditors: amounts falling due after more than one year	13	(36,341)	(43,247)
Total net assets		<u><u>1,487,719</u></u>	<u><u>1,271,043</u></u>
Charity funds			
Restricted funds	14	317,591	135,864
Unrestricted funds	14	1,170,128	1,135,179
Total funds		<u><u>1,487,719</u></u>	<u><u>1,271,043</u></u>


The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 27/09/2024 and signed on their behalf by:


Dr Sabine Hofer
Trustee

The notes on pages 17 to 33 form part of these financial statements.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash from operating activities	16	260,425	155,870
Change in cash and cash equivalents in the year		260,425	155,870
Cash and cash equivalents at the beginning of the year		1,572,277	1,416,407
Cash and cash equivalents at the end of the year	17	1,832,702	1,572,277

The notes on pages 17 to 33 form part of these financial statements

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. General information

The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a charitable company, limited by guarantee, (registration number 06641016 England & Wales) and the Charity Commission (charity number 1126927). The registered office address is Harrison Clark Rickerbys Limited, Ellenborough House, Wellington Street, Cheltenham, Gloucestershire, GL50 1YD.

2. Accounting policies

2.1 Basis of preparation of financial statements

These financial statements present information about the Charity as an individual undertaking. The current period is for the year ended 31 December 2023 ('2023'). The prior period is for the year ending 31 December 2022 ('2022').

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006 and the Charities Act 2011.

The International Society for Pediatric and Adolescent Diabetes meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The Trustees have undertaken detailed planning and forecasting and continue to closely monitor persistent global uncertainties, including inflationary pressures and geopolitical instability. Although the Trustees observed a positive conference income in 2023, there are still uncertainties over future corporate income and income and costs associated with conferences and other educational programs involving travel and logistical expenses.

Despite these challenges, the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.

2.3 Income

Income is recognised in the financial statements when the Charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Membership income is recognised in line with the financial year. Membership income for future years is deferred.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.4 Expenditure

All expenditure is accounted for on an accruals basis. Support costs are apportioned to cost activities based on the estimated amount attributable to that cost in the year on the basis of the estimated time spent on that activity. The irrecoverable element of VAT is included with the item of expense to which it relates.

Charitable activities comprise all expenditure incurred directly relating to the objects of the Charity.

Grants are recognised when a constructive obligation arises that results in the payment being unavoidable.

Governance costs include the costs connected with the Charity's constitutional and statutory requirements.

Charitable activities are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

2.5 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

The functional currencies of ISPAD are considered to be Euros and US Dollars because these are the currencies used by the members of the Society in the primary economic environment in which the charity operates, Europe and the rest of the world. The financial statements are presented in pounds sterling.

2.6 Taxation

As a registered Charity the entity is entitled to taxation exemptions on all its income and gains, properly applied for its charitable purposes.

2.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.

2.8 Cash at bank and in hand

Cash is represented by cash in hand and deposits with financial institutions.

2.9 Creditors

Creditors are recognised once there is a legal or constructive obligation that commits the Charity to the obligation.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.10 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2.11 Fund accounting

Unrestricted funds expendable at the discretion of the Trustees in furtherance of objectives and administration of the Charity.

Restricted funds are to be used for specified purposes laid down by the donor. Expenditure for those purposes is charged to the restricted fund.

3. Critical accounting estimates and areas of judgement

Preparation of the financial statements requires management to make any significant estimates and judgements where necessary. The items in the financial statements where material estimates and judgements have been made include:

Impairment of debtors

The charity makes an estimate of the recoverable value of membership debtors. When assessing impairment management considers historical experience. See note 10 for the net carrying amount of debtors.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

4. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Membership costs	291,638	4,308	295,946
Conference costs	75,361	-	75,361
Grants and Prizes (note 6)	42,070	58,900	100,970
ISPAD Science School for Physicians	-	79,052	79,052
ISPAD Science School for Healthcare Professionals	-	27,030	27,030
PETCA/PETCWA Research and projects	504	13,226	13,730
Allan Drash Fellowship	-	58,880	58,880
Discovery of Insulin (Children's Book)	-	291	291
FID-ISPAD Research Grant	-	16,372	16,372
ISPAD Guidelines	2,697	-	2,697
ISPAD-JDRF Fellowship	-	39,296	39,296
Other	1,985	39,562	41,547
Total 2023	414,255	336,917	751,172

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

4. Analysis of expenditure on charitable activities (continued)

Summary by fund type (continued)

	<i>Unrestricted funds 2022 £</i>	<i>Restricted funds 2022 £</i>	<i>Total 2022 £</i>
Membership costs	146,255	-	146,255
Conference costs	75,229	-	75,229
Grants and Prizes (note 6)	26,573	6,804	33,377
ISPAD Science School for Physicians	-	45,117	45,117
ISPAD Science School for Healthcare Professionals	2,116	21,384	23,500
PETCA/PETCWA Research and projects	1,744	-	1,744
Allan Drash Fellowship	(20,714)	135,790	115,076
Discovery of Insulin (Children's Book)	-	2,759	2,759
FID-ISPAD Research Grant	(213)	42,897	42,684
ISPAD Guidelines	1,405	16,748	18,153
ISPAD-JDRF Fellowship	20,607	140,520	161,127
Other	-	65,402	65,402
Total 2022	253,002	477,421	730,423

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

5. Analysis of expenditure by activities

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Membership costs	41,987	253,959	295,946
Conference costs	67,825	7,536	75,361
Grants and Prizes (note 6)	90,873	10,097	100,970
ISPAD Science School for Physicians	77,471	1,581	79,052
ISPAD Science School for Healthcare Professionals	24,057	2,973	27,030
CDIC Grant	13,661	69	13,730
Allan Drash Fellowship	48,282	10,598	58,880
Discovery of Insulin (Children's Book)	291	-	291
FID-ISPAD Research Grant	16,290	82	16,372
ISPAD Guidelines	2,670	27	2,697
ISPAD-JDRF Fellowship	34,580	4,716	39,296
ADECA	41,547	-	41,547
Total 2023	459,534	291,638	751,172

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

5. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2022 £</i>	<i>Support costs 2022 £</i>	<i>Total funds 2022 £</i>
Membership costs	54,414	91,841	146,255
Conference costs	67,706	7,523	75,229
Grants and Prizes (note 6)	30,039	3,338	33,377
ISPAD Science School for Physicians	44,215	902	45,117
ISPAD Science School for Healthcare Professionals	20,915	2,585	23,500
PETCA/PETCWA Research and projects	1,735	9	1,744
Allan Drash Fellowship	94,362	20,714	115,076
Discovery of Insulin (Children's Book)	2,759	-	2,759
FID-ISPAD Research Grant	42,471	213	42,684
ISPAD Guidelines	17,971	182	18,153
ISPAD-JDRF Fellowship	141,792	19,335	161,127
Other	65,402	-	65,402
<i>Total 2022</i>	<i>583,781</i>	<i>146,642</i>	<i>730,423</i>

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

6. Grants and prizes

	2023 £	2022 £
Special Travel Grants	12,424	4,782
Young Investigator Award	436	-
ISPAD Prize for Innovation	1,853	-
Lestrade Award	1,348	-
Standard Travel Grants	15,683	21,791
Hero Award	1,053	669
Prize Winners	5,496	6,135
Other Travel Grants	62,677	-
	<u>100,970</u>	<u>33,377</u>

Details of the winners of ISPAD prizes and fellowships is available at;

www.ispad.org/?page=ISPADPrizeWinners.

All grants, prizes and fellowships are to individuals. During the year grants were paid to 57 individuals.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

7. Support costs

	2023 £	2022 £
Meeting expenses	-	1,936
Insurance	1,096	820
Bank Charges	3,548	4,106
Credit Card fees	4,363	3,183
Membership Dues	4,853	4,961
Management charge	193,307	162,397
Printing, postage and stationery	-	37
Advertising and promotion	17,171	4,369
Research and Education	1,751	-
Governance costs		
Independent Examiner's fees	10,000	24,823
Professional fees	1,369	-
Legal fees	434	433
Exchange loss/ (gain)	51,341	(65,268)
Webinars	2,369	4,458
Sundry	36	387
	<u>291,638</u>	<u>146,642</u>

Exchange rate gain/loss

This is not a trading '(gain)/loss' as ISPAD does not trade currencies. It is an 'accounting adjustment' and represents the difference in value of non-sterling balances at the year end in comparison to the start of the year where different exchange rates were in effect. As an example a balance of \$10,000 at the start of the financial year might be worth £7,600 (at a USD/GBP exchange rate of 0.76) and at the end of the year that might have changed to £7,870 (at a USD/GBP exchange rate of 0.787). This would result in an apparent gain of £270 while in fact there had been no change to the \$10,000 held.

The foreign exchange loss is included in support costs and was £119,812 (2022: £65,268 gain).

Independent Examiner's fees

The independent examiner's fee reported in 2023 was £10,000. The fee reported during the prior year is significantly higher because this is the first year that an accrual is being input into the accounts to include the current year fees. The figure reported in 2022 is made up of fees for 2022 of £9,500 and fees for 2021 of £15,323.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

8. Independent examiner's remuneration

	2023 £	2022 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	7,000	21,823
Fees payable to the Charity's independent examiner in respect of: All assurance services not included above	<u>3,000</u>	<u>3,000</u>

9. Trustees' remuneration and expenses

During the period, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the period ended 31 December 2023, expenses totalling £9,156 were reimbursed or paid directly to 7 Trustees (2022 - £7,225 to 3 Trustees). Expenses related to travel, accommodation and subsistence.

10. Key management remuneration

The Trustees and Executive Board are the key management of the charity. The key management does not receive any remuneration for their services.

11. Debtors

	2023 £	2022 £
Due within one year		
Trade debtors	48,841	285,838
Other debtors	91,225	-
Prepayments and accrued income	1,633	-
	<u>141,699</u>	<u>285,838</u>

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

12. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	183,830	245,550
Accruals and deferred income	266,511	298,275
	<u>450,341</u>	<u>543,825</u>
	2023 £	2022 £
Deferred income at 1 January 2023	136,687	261,708
Resources deferred during the year	114,539	126,419
Amounts released from previous periods	(125,606)	(251,440)
	<u>125,620</u>	<u>136,687</u>

Deferred income relates to membership subscriptions, corporate membership for future years and the JDRF Fellowship.

13. Creditors: Amounts falling due after more than one year

	2023 £	2022 £
Accruals and deferred income	36,341	43,247

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

14. Statement of funds

Statement of funds - current year

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 December 2023 £
Unrestricted funds					
General Funds - all funds	1,135,179	481,435	(414,255)	(32,231)	1,170,128
Restricted funds					
ISPAD SSHP	7,549	27,458	(25,330)	-	9,677
Alan Drash Fellowship	-	59,025	(58,880)	-	145
Innovation Prize	18,078	-	(801)	-	17,277
Wedcasting Sponsorship	3,254	-	-	-	3,254
Young Investigator's Award	10,707	6,012	-	-	16,719
Lestrade Award	14,992	6,009	(295)	-	20,706
Discovery of Insulin	9,251	-	(291)	-	8,960
ASPED-ISPAD Lilly Diabetes Postgraduate Course	8,809	-	-	-	8,809
JDRF Fellowship	18,585	78,450	(39,296)	-	57,739
Novo Nordisk/Lilly SSP	32,048	63,211	(79,052)	-	16,207
Lilly Prize for Achievement	7,717	6,203	(4,302)	-	9,618
Hero Award	399	6,093	-	-	6,492
ADECA	-	-	(32,231)	32,231	-
FID- ISPAD Grant	4	16,372	(16,372)	-	4
Changing Diabetes in Children	4,471	217,580	(80,067)	-	141,984
	135,864	486,413	(336,917)	32,231	317,591
Total of funds	1,271,043	967,848	(751,172)	-	1,487,719

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

14. Statement of funds (continued)

Statement of funds - prior period

	<i>Balance at 1 July 2020</i>	<i>Income</i>	<i>Expenditure</i>	<i>Transfers in/out</i>	<i>Balance at 31 December 2022</i>
	£	£	£	£	£
Unrestricted funds					
General Funds - all funds	1,067,861	375,027	(273,929)	(33,780)	1,135,179
Restricted funds					
ISPAD SSHP	-	28,933	(21,384)	-	7,549
Innovation Prize	-	106,391	(115,076)	8,685	-
Wedcasting Sponsorship	13,646	6,181	(1,749)	-	18,078
Young Investigator's Award	3,254	-	-	-	3,254
Lestradet Award	6,877	4,927	(1,097)	-	10,707
Discovery of Insulin	10,174	5,915	(1,097)	-	14,992
ASPED-ISPAD Lilly Diabetes Postgraduate Course	-	12,010	(2,759)	-	9,251
JDRF Fellowship	8,809	-	-	-	8,809
Lily Prize for Achievement	2,453	156,652	(140,520)	-	18,585
Hero Award	34,816	42,349	(45,117)	-	32,048
ADECA	3,911	5,999	(2,193)	-	7,717
Changing Diabetes in Children	1,068	-	(669)	-	399
ISPAD Guidelines 2022	-	8,220	(16,748)	8,528	-
ADECA	-	48,835	(65,402)	16,567	-
FID- ISPAD Grant	-	42,687	(42,683)	-	4
Changing Diabetes in Children	-	4,471	-	-	4,471
	85,008	473,570	(456,494)	33,780	135,864
Total of funds	1,152,869	848,597	(730,423)	-	1,271,043

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

15. Statement of Funds (continued)

ISPAD Science School for Healthcare Professionals

This is funds used to support the Science School for Healthcare Professionals which is a three day course in the field of childhood diabetes to learn about research development, statistics and grant writing.

Allan Drash Fellowship

Allan Drash was one of ISPAD's founding members and in his memory ISPAD offers a 6 week clinical fellowship. Applications are invited from members below 45 years of age. A report must be submitted to the ISPAD Steering Committee within 1 year after fellowship.

The ISPAD Prize for Innovation in Pediatric Diabetes Care

Sponsored by NovoNordisk within their DAWN™ Youth Initiative, this prize is for any professional, group or individual who has made a significant (non-commercial) innovation in pediatric diabetes care. DAWN™ Youth is a global programme to guide the wider diabetes community to address the unmet needs of young people with diabetes, their families, peers and healthcare professionals. This prize puts the focus on diabetes in childhood by recognising innovations to improve health and quality of care for children and young people.

Discovery of Insulin

100 years of the discovery of insulin was celebrated in 2021 and 2022. To celebrate, ISPAD prepared various communications across its website and social media. A "comic book" was devised for young people (Insulin: The Incredible Discovery), describing the discovery of Insulin (with drawings by Rebecca Redmond and story by Jade Bryne). The comic book was disseminated at several meetings/events last year.

Webcasting

The webcasting fund was initially created for costs related to ISPAD's first webcasting Platform in 2014 (Annual Conference in Toronto). Since 2015, ISPAD has a new Resource Platform, for which the funding and related costs are now managed as part of the conference budget, managed by K.I.T Group, in close collaboration with ISPAD.

The ISPAD-ASPED Lilly diabetes postgraduate course

The ISPAD/ASPED/Lilly diabetes postgraduate course (previously described as the Post Grad Course Arabian) is an initiative from ASPED in collaboration with ISPAD. The aim of the course is to empower and update physicians practicing in the Arab countries who are involved in the care of young people with diabetes and is intended to be a platform to share expertise, research and development in the field of diabetes.

ISPAD JDRF Fellowship

JDRF has signed a MoU with ISPAD with the aim to award each year for three years starting in 2017, four grants of \$25,000 to award the four best research projects submitted by young researchers, who are ISPAD members, aged 40 or below. The grant can be spent in a hosting center of excellence but also at their own center.

Novo Nordisk/Lilly SSP 2018

These are funds to support the Science School for Physicians.

The remaining restricted funds are donations or grants which must be awarded to individuals.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

15. Statement of Funds (continued)

Hero Award

This award identifies and honours non-clinicians from around the world who have developed projects with a broad impact, thus contributing to improving and transforming the lives of many young people with diabetes. More information can be found here: <https://www.ispad.org/page/ISPADHEROAWARD>.

ISPAD Guidelines 2022

ISPAD's Clinical Practice consensus guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide. Authors include experts from across the globe and a chapter on limited care for developing healthcare systems has also been developed. A great amount of work is involved in reviewing these chapters every four years. In order to ensure consistency and solid research across all chapters, ISPAD paid for the support of a freelancing project officer to help with his specific assignment. The final set of guidelines for 2022 are available here: <https://www.ispad.org/page/ISPADGuidelines2022>

ADECA

The Allied Healthcare Professionals Pediatric Diabetes Educator Course for Africa (ADECA) is a diabetes education and management course that targets qualified nurses and allied health professionals working in Africa and trains them to become pediatric diabetes educators. ADECA is a hybrid course which includes a combination of E-learning and in person (face-to-face) modules.

FID-ISPAD Grant

This grant is for ISPAD members, preferably below the age of 40. The scope of the research grant is related to the identification of a cure for type 1 diabetes, meaning a procedure or therapy that can ensure the normalization and maintenance over time of a normal glucose balance in the absence of external insulin administration. This category includes projects on pathogenesis, prediction, prevention, beta-cell replacement, organ and cell transplantation, tissue regeneration and stem cells, gene therapy.

Explicitly excluded from funding is research on insulin, drugs, glucose sensor technologies, or insulin infusers, which pertain to pharmaceutical and biotechnology companies. Also excluded is research related to complications of diabetes and research related to type 2 diabetes or forms of diabetes other than type 1 diabetes.

The FID-ISPAD Research Grant program is only open to applicants from non-profit institutions or groups of such institutions. One recipient per year is selected, and receives a funding amount of EUR 25,000 for their research.

Changing Diabetes in Children

Changing Diabetes in Children partnered with ISPAD in 2019-2022 with developing training material and workshops in Cambodia to raise awareness about T1D. The funding came from ISPAD and the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ). This fund/activity has therefore been renamed to ISPAD-CDIC- T1D Training (Cambodia).

Changing Diabetes in Children (CDIC)

There is a very recent agreement (2023) with CDIC, which will be relevant for the year end 2023 accounts. Changing Diabetes® in Children is a public-private partnership established in 2009. The partnership provides comprehensive care for children and young people living with type 1 diabetes in low- and middle-income countries. This includes free life-saving medicine and supplies for persons up to 25 years of age.

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

Transfers

During the year ended 31st December 2023 transfers were made as follows:

Transfers totalling £32,231 to the ADECA fund as this was only part funded by restricted funds.

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Current assets	1,491,118	483,283	1,974,401
Creditors due within one year	(284,649)	(165,692)	(450,341)
Creditors due in more than one year	(36,341)	-	(36,341)
Total	1,170,128	317,591	1,487,719

Analysis of net assets between funds - prior period

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Current assets	1,526,917	331,198	1,858,115
Creditors due within one year	(348,491)	(195,334)	(543,825)
Creditors due in more than one year	(43,247)	-	(43,247)
Total	1,135,179	135,864	1,271,043

THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

16. Reconciliation of net movement in funds to net cash flow from operating activities

	2023 £	2022 £
Net income for the year (as per Statement of Financial Activities)	216,676	118,174
Adjustments for:		
(Increase)/ decrease in debtors	144,139	(82,660)
Increase in creditors	(100,390)	120,356
Net cash provided by operating activities	260,425	155,870

17. Analysis of cash and cash equivalents

	2023 £	2022 £
Cash in hand	1,832,702	1,572,277
Total cash and cash equivalents	1,832,702	1,572,277

18. Analysis of changes in net debt

	At 1 July 2020 £	Cash flows £	At 31 December 2021 £
Cash at bank and in hand	1,572,277	260,425	1,832,702
	1,572,277	260,425	1,832,702

19. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 December 2023.